ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 914

Prognosis for the Year 2030: The Consultation Prevalence of Osteoarthritis in Sweden May Increase by 50%

Aleksandra Turkiewicz1, Ingemar F. Petersson2, Jonas Björk3, Leif E. Dahlberg1 and Martin Englund1, 1Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, 2Lund University, Lund, Sweden, 3Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden, Lund, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Knee and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose: To project the future prevalence of knee and hip osteoarthritis (OA) leading to doctor consultation.

Methods: The Skåne Health Care Register is a legislative, mandatory register in Skåne County, Sweden (total population 1.3 million), based on physicians’ International Classification of Diseases (ICD) 10 diagnostic codes. We used observational data on the consultation prevalence of the knee (M17) and hip OA (M16) by the 31st Dec 2011 based on the SHCR data from years 1999-2011. The age-specific (age 20-65 and >65 years) population structure prognosis and its confidence intervals for Skåne were provided by Statistics Sweden. We assumed two scenarios. In scenario 1 (conservative) we assumed that the age-specific prevalence would remain constant. In scenario 2 we assumed that the age-specific prevalence would increase relatively by 2.6% per year in the first 10 years and by 2% per year in the next 10 years for those aged ≤65 and by 1.6% per year in the first 10 years and by 1.2% per year in the next 10 years for the population >65. Initial values for that increase are based on the previously published changes in the prevalence of arthritis between 1994 and 2002 in Canada (Perrucio et al 2006). The reasons for this observed increase are not fully understood but the increase in obesity is the main plausible cause.

Results: In the conservative scenario which solely depends on changes in age distribution of the population, the consultation prevalence of knee OA in adults (aged 20+) will increase from 9.0% in 2011 to 9.9% in 2030. The hip OA consultation prevalence will increase from 4.0% in 2011 to 4.6% in 2030. Assuming the second scenario, i.e., an increase in age-specific prevalence, the consultation prevalence of knee and hip OA in adults will increase to 13.6% and 6.1% in 2030, respectively.

Conclusion: There is a risk for a 50% increase in OA prevalence in 20 years from now. Results suggest that fighting the negative impact of obesity will be of primary importance to reduce the occurrence of the OA in the future.

Figure. The prognosis of knee and hip OA consultation prevalence in Swedish adults (aged 20+). Vertical bars represent the confidence intervals of the prognosis due to uncertainty of the population prognosis.

 


Disclosure:

A. Turkiewicz,
None;

I. F. Petersson,
None;

J. Björk,
None;

L. E. Dahlberg,
None;

M. Englund,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prognosis-for-the-year-2030-the-consultation-prevalence-of-osteoarthritis-in-sweden-may-increase-by-50/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology